Inc. (NASDAQ:INCR) Files An 8-K Regulation FD Disclosure
Item 7.01. Regulation FD
On June6, 2017, management of Monogram Residential Trust,Inc.
(the Company) will begin utilizing a presentation in connection
with investor meetings. The full text of the presentation is
furnished as Exhibit99.1 hereto. Additionally, the Company has
posted a copy of the presentation on the Investor Relations
portion of its website at www.monogramres.com.
The information in this Current Report on Form8-K, including the
exhibit attached hereto, is being furnished and shall not be
deemed filed for purposes of Section18 of the Securities Exchange
Act of 1934, as amended (the Exchange Act), or otherwise subject
to the liabilities of that section, nor shall the information be
deemed incorporated by reference in any filing under the
Securities Act of 1933, as amended, or the Exchange Act.
Item 9.01. Financial Statements and
Exhibits.
Exhibits:
|
ExhibitNo. |
|
Description |
|
99.1 |
Company Presentation |
About Inc. (NASDAQ:INCR)
INC Research Holdings, Inc. is a global contract research organization (CRO). The Company is focused on Phase I to Phase IV clinical development services for the biopharmaceutical and medical device industries. The Company operates through two segments: Clinical Development Services and Phase I Services. The Company’s Clinical Development Services segment offers all clinical development services, including full-service global studies, as well as ancillary services, such as clinical monitoring, investigator recruitment, patient recruitment, data management, study reports to assist customers with their drug development process, quality assurance audits and specialized consulting services. The Company’s Phase I Services segment focuses on clinical development services for Phase I trials, which include scientific exploratory medicine, first-in-human studies through proof-of-concept stages and support for Phase I studies in established compounds.
